Laetrile / Amygdalin as Cancer Treatment

HYPOTHESIS CRITIC  /  REVIEW EXPLAINER
Laetrile: laboratory activity and clinical benefit — compare explanations
CONCEPTUAL DIAGRAM  •  Original site diagram  •  Not experimental measurements
THE REVIEW'S TAKEAWAY
Laboratory findings have not established meaningful cancer benefit from promoted human regimens, and cyanide poisoning is a documented risk.
CLAIM / SIMPLE EXPLANATION
01
Tumour-selective killing
02
Normal tissues spared
03
Clinical tumour control
The historical treatment programme reported no substantive clinical benefit; it was not randomized.
BEST FIT TO REVIEWED EVIDENCE
01
Metabolism + exposure
02
Model effects + toxicity
03
No validated clinical bridge
Partial experimental selectivity remains relevant while route-dependent cyanide harm has its own evidence base.
WHY THE REVIEW DISTINGUISHES THEM
The historical human treatment programme found no substantive benefit, although it was not a randomized trial. Cell and animal findings remain research leads; new experimental formulations are different from the promoted oral or injected regimens. Cyanide risk depends on the route and on what is taken with the compound.
Relationships are schematic; arrow lengths do not encode effect size or certainty.
Record: laetrile-cancer-treatment  •  HSEF v5.3 review and source-access limitations

Rank 1: Route-dependent nonselective cyanide toxicity — Microbial or food-enzyme activation and coingestions generate systemic cyanide rather than a reliably tumour-selective clinical exposure.

Rank 2: Contextual cell activity without a clinical exposure bridge — Culture effects and engineered delivery can be real without being achievable as a safe effective promoted human regimen.

Rank 3: Selection and concurrent treatment explain apparent clinical benefit — Solicited favorable cases and provider impressions can reflect selection, prior treatment and subjective endpoints rather than drug efficacy.

Rank 4: Selective tumour toxicity produces clinical benefit — Promoted laetrile exposure safely targets tumour cells and improves human disease control.

HYPOTHESIS CRITIC  /  REVIEW EXPLAINER
Laetrile: laboratory activity and clinical benefit — evidence and next test
CONCEPTUAL DIAGRAM  •  Original site diagram  •  Not experimental measurements
THE REVIEW'S TAKEAWAY
Laboratory findings have not established meaningful cancer benefit from promoted human regimens, and cyanide poisoning is a documented risk.
DIFFERENT EVIDENCE ANSWERS DIFFERENT QUESTIONS
Cells + animals
Positive experimental findings support partial mechanistic plausibility.
LIMIT / SCOPE
Model exposures and newer formulations do not establish historical-regimen benefit.
Human programme
The historical treatment programme reported no substantive benefit.
LIMIT / SCOPE
Its nonrandomized design limits precise efficacy estimates.
Toxicity
Systemic cyanide exposure is a documented route-dependent concern.
LIMIT / SCOPE
Toxicity alone does not determine the benefit verdict; generic care-refusal cohorts are not laetrile-specific.
A USEFUL NEXT TEST
First establish selective effects at realistic exposures with suitable normal-cell, tumour and toxicity comparisons, before considering any justified clinical study alongside effective care.
Relationships are schematic; arrow lengths do not encode effect size or certainty.
Record: laetrile-cancer-treatment  •  HSEF v5.3 review and source-access limitations

Proposed tests: 1 test design(s) are registered in the scorecard.

In plain terms, researchers would change the proposed cause, check that it changed as intended, then measure a meaningful outcome while controlling plausible alternatives. The result should be able to support or count against the claim—not only show that a pathway exists.